Loading...
We might have thought the COVID-19 pandemic would be over by year-end, but experts now say—and the omicron variant suggests—the virus will likely always be with us. What pandemic lessons has the industry learned that can help tackle longtime challenges—such as speeding up drug development, adding new diversity into clinical trials, launching new products and, of course, identifying the next cutting edge in science?
Join us on January 18-20, 2022 for this must-attend virtual event featuring panel discussions, executive interviews, and valuable networking opportunities. We'll feature top leaders and innovators from Alnylam, Amgen, Bayer, Cigna, Eli Lilly, J&J, Novo Nordisk, Roche and more. Featured speakers include: Kevin Ali CEO Organon Al Boyle Chief Technical Operations & Quality Officer Alnylam Pharmaceuticals Cristin Hubbard Global Head of Diagnostics Partnering Roche David A. Ricks Chairman and CEO Eli Lilly and Company Melinda Richter Global Head Johnson & Johnson Innovation - JLABS Christian Rommel, Ph.D. Global Head of Research & Development Bayer Pharmaceuticals Shawna Dodds Vice President of Product Development Cigna John V. Oyler CEO BeiGene To view our full line-up of speakers, click here.
With the transformations brought about by the pandemic, timely and trustworthy information are needed now more than ever. We'll discuss what’s working, what isn’t and what new opportunities exist. Topics include: Trial diversity The post-COVID supply chain The future of women's health The next mRNA wave Virtual-first health plans Biopharma collaboration And more...We look forward to engaging with you next month. Reserve your spot today.
Thank You To Our Sponsors EXECUTIVE PLATINUM
PLATINUM
GOLD SILVER
If you no longer wish to receive promotion on this event, simply unsubscribe.
|
Loading...
Loading...